This double-blind , parallel-group , single-center study enrolled and randomized @ healthy subjects ( @ men , @ women ) to receive subcutaneous doses of teduglutide @ mg or placebo ( @:@ ratio ; @:@ ) once daily on Days @ through @ in the morning .